| Dr Margot Waldman, DPM | |
|
102 Mary Alice Park Rd Ste 201, Cumming, GA 30040-2682 | |
| (678) 262-4040 | |
| (678) 262-4060 |
| Full Name | Dr Margot Waldman |
|---|---|
| Gender | Female |
| Speciality | Podiatry |
| Experience | 10 Years |
| Location | 102 Mary Alice Park Rd Ste 201, Cumming, Georgia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609287291 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Northeast Georgia Medical Center, Inc | Gainesville, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northeast Georgia Podiatry Llc | 8729356662 | 2 |
News Archive
Using extensive genetic data compiled by the UK10K project, an international team of researchers led by Dr. Brent Richards of the Lady Davis Institute at the Jewish General Hospital has identified a genetic variant near the gene EN1 as having the strongest effect on bone mineral density (BMD) and fracture identified to date.
Extending treatment with the anticoagulant bivalirudin for at least four hours after completion of percutaneous coronary intervention (PCI) does not improve outcomes compared to stopping the treatment immediately after the procedure, according to results from the MATRIX Treatment Duration trial.
Medicago Inc., a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has been awarded $946,000 in funding by U.S.-based PATH pursuant to a research collaboration agreement. Medicago and PATH will work together on a broad coverage influenza vaccine based on Medicago's proprietary plant-based Virus-Like Particle (VLP) technologies for the developing world.
New data presented today at the International Liver CongressTM confirm the antiviral activity of fluvastatin - commonly used as a cholesterol-lowering treatment - in patients with chronic hepatitis C.
› Verified 2 days ago
| Provider Name | Forsyth Foot & Ankle Associates Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1922367994 PECOS PAC ID: 8527224781 Enrollment ID: O20120717000220 |
News Archive
Using extensive genetic data compiled by the UK10K project, an international team of researchers led by Dr. Brent Richards of the Lady Davis Institute at the Jewish General Hospital has identified a genetic variant near the gene EN1 as having the strongest effect on bone mineral density (BMD) and fracture identified to date.
Extending treatment with the anticoagulant bivalirudin for at least four hours after completion of percutaneous coronary intervention (PCI) does not improve outcomes compared to stopping the treatment immediately after the procedure, according to results from the MATRIX Treatment Duration trial.
Medicago Inc., a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has been awarded $946,000 in funding by U.S.-based PATH pursuant to a research collaboration agreement. Medicago and PATH will work together on a broad coverage influenza vaccine based on Medicago's proprietary plant-based Virus-Like Particle (VLP) technologies for the developing world.
New data presented today at the International Liver CongressTM confirm the antiviral activity of fluvastatin - commonly used as a cholesterol-lowering treatment - in patients with chronic hepatitis C.
› Verified 2 days ago
| Provider Name | Northeast Georgia Podiatry Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1225575855 PECOS PAC ID: 8729356662 Enrollment ID: O20170616001359 |
News Archive
Using extensive genetic data compiled by the UK10K project, an international team of researchers led by Dr. Brent Richards of the Lady Davis Institute at the Jewish General Hospital has identified a genetic variant near the gene EN1 as having the strongest effect on bone mineral density (BMD) and fracture identified to date.
Extending treatment with the anticoagulant bivalirudin for at least four hours after completion of percutaneous coronary intervention (PCI) does not improve outcomes compared to stopping the treatment immediately after the procedure, according to results from the MATRIX Treatment Duration trial.
Medicago Inc., a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has been awarded $946,000 in funding by U.S.-based PATH pursuant to a research collaboration agreement. Medicago and PATH will work together on a broad coverage influenza vaccine based on Medicago's proprietary plant-based Virus-Like Particle (VLP) technologies for the developing world.
New data presented today at the International Liver CongressTM confirm the antiviral activity of fluvastatin - commonly used as a cholesterol-lowering treatment - in patients with chronic hepatitis C.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Margot Waldman, DPM 102 Mary Alice Park Rd Ste 201, Cumming, GA 30040-2682 Ph: (678) 262-4040 | Dr Margot Waldman, DPM 102 Mary Alice Park Rd Ste 201, Cumming, GA 30040-2682 Ph: (678) 262-4040 |
News Archive
Using extensive genetic data compiled by the UK10K project, an international team of researchers led by Dr. Brent Richards of the Lady Davis Institute at the Jewish General Hospital has identified a genetic variant near the gene EN1 as having the strongest effect on bone mineral density (BMD) and fracture identified to date.
Extending treatment with the anticoagulant bivalirudin for at least four hours after completion of percutaneous coronary intervention (PCI) does not improve outcomes compared to stopping the treatment immediately after the procedure, according to results from the MATRIX Treatment Duration trial.
Medicago Inc., a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has been awarded $946,000 in funding by U.S.-based PATH pursuant to a research collaboration agreement. Medicago and PATH will work together on a broad coverage influenza vaccine based on Medicago's proprietary plant-based Virus-Like Particle (VLP) technologies for the developing world.
New data presented today at the International Liver CongressTM confirm the antiviral activity of fluvastatin - commonly used as a cholesterol-lowering treatment - in patients with chronic hepatitis C.
› Verified 2 days ago
Dr. Pinecca J Patel-raval, DPM Podiatrist Medicare: Medicare Enrolled Practice Location: 5830 Bond St, Ste 200, Cumming, GA 30040 Phone: 770-455-4009 Fax: 770-455-4065 | |
Dr. Latashia J Webb, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 2450 Atlanta Hwy, 402, Cumming, GA 30040 Phone: 678-807-8320 Fax: 678-456-8650 | |
Stephanie C Merritt, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 1400 Northside Forsyth Dr, Suite 220, Cumming, GA 30041 Phone: 678-208-0700 Fax: 678-208-0705 | |
Village Podiatry Group, Llc. Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 1505 Northside Blvd., Suite 2600, Cumming, GA 30041 Phone: 678-208-0700 Fax: 770-771-5312 | |
Foot And Ankle Wellness Center Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 416 Pirkle Ferry Rd Ste J500, Cumming, GA 30040 Phone: 678-513-8777 Fax: 678-513-8999 | |
Michael C. Mcglamry, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 102 Mary Alice Park Drive, Suite 502, Cumming, GA 30040 Phone: 678-262-4040 Fax: 678-262-4060 |